US 2016/0108105 A1 · HUMAN IGG4 FC POLYPEPTIDE VARIANT

Abstract

Disclosed is a human IgG4 Fc polypeptide variant, including a modified CH2 domain of human IgG4 Fc, wherein the modification contains a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with a 4-18 consecutive amino acid sequence from the N-terminus of human IgA1 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgA2 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgD CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgE CH2, or a 4-18 consecutive amino acid sequence from the N-terminus of human IgM CH2. The Fc variant imparts to a biologically active polypeptide—the modified Fc variant with a prolonged in-vivo half-life and reduced immunogenic reaction.

Claims27

Dependent claims

A modified human IgG4 Fc polypeptide comprising a modified CH2 domain of human IgG4 Fc, and a CH3 domain of human IgG4 Fc in an N-terminal to C-terminal direction,

wherein the modification to the CH2 domain of human IgG4 Fc comprises a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with one selected from the group consisting of a 4-18 consecutive amino acid sequence from the N-terminus of a CH2 domain of human IgA1 Fc, a 4-18 consecutive amino acid sequence from the N-terminus of a CH2 domain of human IgA2 Fc, a 4-18 consecutive amino acid sequence from the N-terminus of a CH2 domain of human IgD Fc, a 4-18 consecutive amino acid sequence from the N-terminus of a CH2 domain of human IgE Fc, and a 4-18 consecutive amino acid sequence from the N-terminus of a CH2 domain of human IgM Fc.

Dependencies are inferred from the claim text.

Human igg4 fc polypeptide variant

Life of this patent

Human igg4 fc polypeptide variant

Life of this patent

Abstract

Claims27